Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of Hypoxia and Re-oxygenation Imaging in Pancreatic Cancer Using Positron Emission Tomography (PET) With [18F] Fluoroazomycin-arabinoside (FAZA PET) and Magnetic Resonance Imaging (MRI)

NCT04395469 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04395469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04395469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of Hypoxia and Re-oxygenation Imaging in Pancreatic Cancer Using Positron Emission Tomography (PET) With [18F] Fluoroazomycin-arabinoside (FAZA PET) and Magnetic Resonance Imaging (MRI)
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Active, not recruiting
Start date
May 18, 2021
Completion date
March 31, 2027
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic adenocarcinoma, pancreatic adenocarcinoma non-resectable, unresectable pancreatic cancer